- 4basebio and Genezen have expanded their non-exclusive collaboration to provide drug developers access to 4basebio’s Research Use Only, High-Quality, and GMP-grade hpDNA® programs.
- The collaboration is intended to support viral vector applications and provide cell and gene therapy developers with a streamlined path toward clinical development.
4basebio has expanded its non-exclusive collaboration with Genezen, a viral vector contract development and manufacturing organization (CDMO), to provide drug developers with access to its enzymatically produced, cell-free hpDNA® across Research Use Only, High-Quality and GMP-grade development and clinical programs.
Under the expanded collaboration, Genezen will offer access to 4basebio’s synthetic DNA developed for viral vector applications. The companies said the arrangement is intended to provide cell and gene therapy developers with a more streamlined path from DNA development to viral vector production and clinical development.
4basebio’s manufacturing process uses an enzymatic, cell-free approach that eliminates bacterial backbone sequences and antibiotic resistance genes from the DNA starting material. In AAV production, the company’s hpDNA template has demonstrated comparable titers to plasmid DNA while requiring approximately 30% less DNA mass and transfection reagent.
The companies said the cell-free manufacturing approach can also shorten DNA production timelines compared with traditional plasmid manufacturing. This is intended to help developers move from sequence development to viral vector production more efficiently while supporting process efficiency and scalability.
“As the cell and gene therapy field continues to mature, developers need manufacturing solutions that not only address today’s challenges, but are designed with the needs of later-stage development in mind.”
Susan D’Costa, Chief Technical and Commercial Officer at Genezen
